Related Experiment Video

Updated: Aug 29, 2026

Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells
09:27

Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells

Published on: April 2, 2021

[symbol: see text]Caspofungin and [symbol: see text]voriconazole for fungal infections

    Drug and Therapeutics Bulletin
    |February 11, 2004
    PubMed

    Insights

    New antifungals, caspofungin (an echinocandin) and voriconazole (a triazole), offer effective treatments for severe systemic fungal infections like invasive candidiasis and aspergillosis, presenting alternatives to traditional therapies.

    Area of Science:

    • Mycology
    • Infectious Diseases
    • Pharmacology

    Background:

    • Systemic fungal infections pose significant treatment challenges and mortality risks.
    • Established treatments include amphotericin B formulations and triazoles (fluconazole, itraconazole).
    • Severe infections caused by Candida spp. and Aspergillus spp. necessitate novel therapeutic options.

    Purpose of the Study:

    • To evaluate the role of two new antifungal agents, caspofungin and voriconazole, in managing severe fungal infections.
    • To compare the efficacy and safety profiles of these novel agents against existing treatments.

    Main Methods:

    • Review of clinical data and published studies on caspofungin and voriconazole.
    • Comparative analysis of treatment outcomes for invasive candidiasis and invasive aspergillosis.
    • Assessment of safety profiles and toxicity compared to conventional antifungals.

    Main Results:

    • Caspofungin, an echinocandin, is presented as a less toxic alternative to amphotericin B for invasive candidiasis.
    • Voriconazole, a triazole, demonstrates improved survival rates in invasive aspergillosis compared to amphotericin B.
    • Both agents represent advancements in treating severe, life-threatening fungal infections.

    Conclusions:

    • Caspofungin and voriconazole offer valuable new therapeutic options for severe systemic fungal infections.
    • These agents provide improved efficacy and/or safety profiles compared to established treatments.
    • Their integration into clinical practice is crucial for managing invasive candidiasis and aspergillosis.

    More Related Videos

    Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance08:45

    Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

    Published on: December 28, 2017

    Related Concept Videos

    Antifungal Agents01:15

    Antifungal Agents

    Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
    Candidiasis01:20

    Candidiasis

    Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
    Cryptococcal Meningitis01:27

    Cryptococcal Meningitis

    Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
    Fungal Group Zygomycota01:29

    Fungal Group Zygomycota

    Zygomycota, previously classified as a distinct fungal group, are primarily terrestrial, saprophytic molds that play a crucial role as decomposers. Recent phylogenetic studies have revealed that these fungi are now divided into two major clades — Mucoromycota, which includes many symbiotic species, and Zoopagomycota, which primarily consists of parasitic and pathogenic fungi. These groups exhibit distinct ecological roles and reproductive strategies while sharing key structural and...
    Antiviral Nucleoside Inhibitors01:22

    Antiviral Nucleoside Inhibitors

    Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...